公司状况 2026年1月10日：董事会审议通过《关于使用闲置募集资金进行现金管理的议案》，计划使用不超过 1000万元闲置募集资金购买期限不超过6个月的低风险理财产品，旨在提高资金使用效率。 资金动向 经济观察网辰光医疗近期事件主要集中在2026年1月，涉及股东减持、公司治理变动及财务表现等方 面。 高管变动 2026年1月12日：公司公告显示，股东田丽芬于2025年11月13日至2026年1月9日期间通过集中竞价减持 15.65万股，持股比例由5.7139%降至5.5316%。其与一致行动人上海复孵科技有限公司合计持股比例由 8.1823%降至8.0000%，触及权益变动披露阈值。 业绩经营情况 2026年1月29日：公司披露2025年度业绩预告，预计归母净利润亏损5300万元至6600万元(上年同期亏损 6090万元)。业绩变动主要受磁共振系统行业竞争加剧影响，1.5T产品销售收入下滑，且7.0T科研用产 品未实现销售。 以上内容基于公开资料整理，不构成投资建议。 2026年1月26日：辰光医疗获融资买入35.76万元，融资净买入35.76万元，融资余额达1734.95万元，占 流通市值的1.28%，处于 ...

2月4日辰光医疗发布公告《辰光医疗:持股5%以上股东减持股份结果公告》，其股东田丽芬于2026年1 月10日至2026年1月14日间合计减持7.0万股，占公司目前总股本的0.0815%，变动期间该股股价上涨 7.42%，截止1月14日收盘报17.38元。 截至2026年2月4日收盘，辰光医疗(920300)报收于14.87元，上涨0.95%，换手率2.01%，成交量1.34万 手，成交额1990.93万元。 当日关注点 交易信息汇总资金流向 上海辰光医疗科技股份有限公司持股5%以上股东田丽芬在2025年11月13日至2026年1月14日期间通过集 中竞价方式减持公司股份226,501股，占公司总股本的0.2638%，减持价格区间为14.99-18.01元/股，累计 减持金额3,875,008.57元。本次减持后，田丽芬持有公司股份4,678,693股，占总股本比例5.4500%。减持 计划尚未完成，减持时间区间已届满，减持事项与此前披露的计划一致。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 2月4日主力资金净流入28.37万元 ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经讯，辰光医疗2月4日发布公告称，公司持股5%以上股东田丽芬2025年11月13日至2026年1月14日减 持约23万股，减持金额约388万元，减持价格区间为14.99元/股~18.01元/股，减持方式为集中竞价。减 持后田丽芬持有约468万股，持股比例为5.45%。 （记者 曾健辉） ...

辰光医疗发布业绩预告，预计2025年全年归属净利润亏损5300万元至6600万元。 公司公告汇总2025年年度业绩预告公告 截至2026年1月29日收盘，辰光医疗(920300)报收于14.99元，下跌1.51%，换手率2.55%，成交量1.69万 手，成交额2558.3万元。 当日关注点 交易信息汇总资金流向 1月29日主力资金净流出128.01万元，占总成交额5.0%；游资资金净流出196.64万元，占总成交额 7.69%；散户资金净流出21.33万元，占总成交额0.83%。 业绩披露要点业绩预告 上海辰光医疗科技股份有限公司预计2025年度归属于上市公司股东的净利润为-5,300万元至-6,600万 元，较上年同期亏损有所收窄。本期业绩变动主要原因系公司营业收入下降，受磁共振整机行业竞争加 剧影响，1.5T磁共振系统销售收入减少；同时7.0T磁共振系统因属科研用小众产品，2025年未实现销 售，进一步影响收入。公告所载财务数据为初步核算结果，未经审计，最终数据以2025年年度报告为 准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投 ...

辰光医疗2025年三季报显示，前三季度公司主营收入6774.26万元，同比下降21.33%；归母净利 润-1933.07万元，同比下降21.77%；扣非净利润-2148.9万元，同比下降3.01%；其中2025年第三季度， 公司单季度主营收入2038.99万元，同比下降29.57%；单季度归母净利润-451.3万元，同比上升3.33%； 单季度扣非净利润-528.12万元，同比上升9.47%；负债率48.48%，投资收益23.9万元，财务费用385.49 万元，毛利率49.73%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，辰光医疗发布业绩预告，预计2025年全年归属净利润亏损5300万元至6600万元。 公告中解释本次业绩变动的原因为： 2025年度公司营业收入有所下降,公司营收增长仍受磁共振整机行业竞争格局影响。2025年中国磁共振 系统市场保持持续竞争态势,特别是头部企业针对集采"带量采购,以量换价"的政策,医学影像设备行业中 标价同比大幅下降,因此公司的1.5T磁共振系统销售收入受到影响。此外公司7.0T ...

Core Viewpoint - Chuangguang Medical announced the completion of its fundraising project "Research and Custom Superconducting Magnet Development Project" by December 18, 2025, and the funds have been fully utilized as per regulations [2] Group 1 - The company has completed the construction of the fundraising project and it has reached the predetermined usable status [2] - The remaining balance of the fundraising account, amounting to 947,791.67 yuan (including interest income), has been transferred to the company's general bank account for working capital supplementation [2] - The special fundraising account was officially closed on January 14, 2026, to facilitate the management of the raised funds [2]

Group 1 - The core point of the article is that Chen Guang Medical (920300) experienced a significant increase of 12.56% in its stock price, with a trading volume of 2.75 billion yuan and a turnover rate of 24.13% on the day [1][2] - Institutional investors net bought 3.53 million yuan, while brokerage seats collectively net sold 12.28 million yuan [1][2] - The stock was listed on the exchange due to its high turnover rate, with the top five brokerage seats contributing a total transaction volume of 63.01 million yuan, where the buying amount was 27.13 million yuan and the selling amount was 35.88 million yuan, resulting in a net sell of 8.75 million yuan [2] Group 2 - The top buying brokerage seat was an institutional specialized seat, which bought 6.28 million yuan and sold 2.75 million yuan, resulting in a net purchase of 3.53 million yuan [2] - The second largest buying seat was Dongfang Securities, which bought 6.15 million yuan without any selling [2] - The selling activities were led by CITIC Securities, which sold 5.45 million yuan while buying only 0.52 million yuan [2]

Group 1 - The core point of the article is that Changuang Medical (920300) was featured on the trading leaderboard due to a significant trading volume and turnover rate on January 5, 2026, with a turnover rate of 24.13% and a transaction amount of 275 million yuan [1][3]. - The total number of shares traded for Changuang Medical on that day was approximately 16.06 million shares [1]. - The leading buyer was an institutional investor, purchasing approximately 6.28 million yuan worth of shares, while the main seller was CITIC Securities, selling around 5.45 million yuan [1][2]. Group 2 - The trading data shows that the top three buying institutions included Dongfang Securities and Guotou Securities, with buying amounts of approximately 6.15 million yuan and 4.91 million yuan, respectively [2]. - The selling data indicates that the top three selling institutions were CITIC Securities, Jianghai Securities, and Guojin Securities, with selling amounts of approximately 5.45 million yuan, 5.43 million yuan, and 5.24 million yuan, respectively [2]. - The overall trading activity reflects a high level of interest in Changuang Medical, as evidenced by the substantial turnover and participation from both institutional buyers and sellers [1][2].

Core Viewpoint - The A-share market is experiencing a localized surge in the controlled nuclear fusion concept, with notable stocks such as Wangzi New Materials hitting the daily limit up and Libet approaching the limit up [1] Group 1: Market Performance - Wangzi New Materials has reached the daily limit up, indicating strong investor interest [1] - Libet has seen significant price movement, nearing the daily limit up [1] - Other companies such as Guoguang Electric, Guoji Heavy Industry, Hezhuan Intelligent, Changfu Shares, and Chenguang Medical are also experiencing upward trends [1] Group 2: Industry Outlook - The 2026 Nuclear Fusion Energy Technology and Industry Conference is scheduled to take place from January 16 to 17, 2026, in Hefei, Anhui [1] - According to a report by Zheshang Securities, the global nuclear fusion equipment market is expected to reach an average annual scale of 266 billion yuan by 2035 [1]

Core Insights - The medical device sector experienced a slight increase of 0.01% on October 23, with Chen Guang Medical leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index also rose by 0.22% to 13025.45 [1] Medical Device Sector Performance - Chen Guang Medical (code: 920300) saw a significant rise of 16.01%, closing at 19.20 with a trading volume of 126,000 shares and a transaction value of 230 million [1] - Other notable gainers included Shuoshi Biology (code: 6628899) with a 7.07% increase, closing at 75.38, and Kangwei Century (code: 688426) which rose by 5.17% to 28.70 [1] - Conversely, the sector also had some decliners, with Toukeng Life (code: 300642) dropping by 6.19% to 24.26, and Rejing Biology (code: 688068) decreasing by 4.07% to 165.15 [2] Capital Flow Analysis - The medical device sector experienced a net outflow of 542 million from institutional investors, while retail investors saw a net inflow of 373 million [2] - Notable net inflows from retail investors were observed in several companies, including Sainuo Medical (code: 688108) with a net inflow of 1.33 billion [3] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors remain active in the market [2][3]